Eisai Co., Ltd. and Biogen Inc. have introduced encouraging findings from their Lecanemab in Early Alzheimer’s Disease (LEADER) Study, revealing that 82.5% of members both remained secure or confirmed enchancment over a median of 17 months of remedy.
The outcomes, offered on the Alzheimer’s Association International Conference 2026, point out that LEQEMBI remedy might assist sluggish cognitive decline and preserve every day functioning in sufferers with early Alzheimer’s illness. The research demonstrated constant outcomes throughout varied demographics, together with intercourse, race, ethnicity, and APOE genotype.
The LEADER Study, a complete multicenter, real-world, retrospective research, assessed 432 sufferers with early Alzheimer’s illness. Of these, 75.9% remained secure, whereas 6.6% improved from delicate AD dementia to delicate cognitive impairment resulting from AD. The research additionally highlighted that almost 87% of sufferers opted to proceed with LEQEMBI remedy.
Among members, 155 transitioned to once-every-four-weeks intravenous upkeep remedy, with 81% sustaining stability or exhibiting enchancment. A smaller group of 14 sufferers shifted to once-weekly subcutaneous upkeep remedy, with 85.7% staying secure.
Safety observations within the research had been in step with the U.S. FDA-approved label for LEQEMBI. Amyloid-related imaging abnormalities (ARIA) had been famous in 12.3% of sufferers, with most circumstances being asymptomatic and delicate. The incidence of ARIA amongst sufferers on antithrombotic remedy was similar to these not on such medicine.
The research’s findings underscore the potential long-term advantages of steady LEQEMBI remedy for early Alzheimer’s illness, providing a promising possibility for slowing illness development in numerous medical settings.